Noninvasive Delivery of Biologicals to the Brain.

Sheldon Jordan, Margaret Zielinski, Marcin Kortylewski, Taylor Kuhn, Alexander Bystritsky

Open access · greenAbstract read

In one paragraph

Article in Focus (American Psychiatric Publishing), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.1field-weighted citation impact, top 66% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sheldon JordanDepartment of Neurology, University of California, Los Angeles and Department of Neurology, University of Southern California, Los Angeles (Jordan);Neurological Associates-The Interventional Group, Los Angeles (Jordan, Zielinski);Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Los Angeles (Kortylewski);Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (Kuhn, Bystritsky).

Margaret ZielinskiDepartment of Neurology, University of California, Los Angeles and Department of Neurology, University of Southern California, Los Angeles (Jordan);Neurological Associates-The Interventional Group, Los Angeles (Jordan, Zielinski);Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Los Angeles (Kortylewski);Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (Kuhn, Bystritsky).

Marcin KortylewskiDepartment of Neurology, University of California, Los Angeles and Department of Neurology, University of Southern California, Los Angeles (Jordan);Neurological Associates-The Interventional Group, Los Angeles (Jordan, Zielinski);Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Los Angeles (Kortylewski);Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (Kuhn, Bystritsky).

Taylor KuhnDepartment of Neurology, University of California, Los Angeles and Department of Neurology, University of Southern California, Los Angeles (Jordan);Neurological Associates-The Interventional Group, Los Angeles (Jordan, Zielinski);Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Los Angeles (Kortylewski);Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (Kuhn, Bystritsky).

Alexander BystritskyDepartment of Neurology, University of California, Los Angeles and Department of Neurology, University of Southern California, Los Angeles (Jordan);Neurological Associates-The Interventional Group, Los Angeles (Jordan, Zielinski);Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Los Angeles (Kortylewski);Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (Kuhn, Bystritsky).

Los Angeles Medical Center · US

Funding

Cell-Selective CpG-STAT3 Inhibitors for Radioimmunotherapy of Malignant GliomaR01CA215183 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI KORTYLEWSKI, MARCIN · 2018 to 2022

$2.3M

NCI NIH HHS R01 CA215183

6 · The paper itself

Abstract

In the past, psychotherapy and neuropharmacological approaches have been the most common treatments for disordered thoughts, moods, and behaviors. One new path of brain therapeutics is in the deployment of noninvasive approaches designed to reprogram brain function at the cellular level. Treatment at the cellular level may be considered for a wide array of disorders, ranging from mood disorders to neurodegenerative disorders. Brain-targeted biological therapy may provide minimally invasive and accurate delivery of treatment. The present article discusses the hurdles and advances that characterize the pathway to this goal.

Indexed as

biological therapybrain-targetedNeuroimaging - PS0398non-invasivePharmacokinetics - AJP0064

Identifiers

PMID35746928

DOI10.1176/appi.focus.20210028

PMCPMC9063603

OpenAlexW4206937260

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.